WVE Files 8-K: Furnished Corporate Presentation Available on IR Site

Rhea-AI Filing Summary

Event: On August 5, 2025, Wave Life Sciences Ltd. (WVE) filed a Form 8-K disclosing an updated corporate presentation.

Details: The Company stated the presentation, which it uses to "provide updates and summaries of its business," is available in the "For Investors & Media" section of its website at http://ir.wavelifesciences.com/ and is furnished as Exhibit 99.1 to this Current Report. The disclosure is made under Item 7.01 (Regulation FD Disclosure) and expressly notes the presentation is furnished and not "filed" for purposes of Section 18 of the Exchange Act. The exhibits list also includes a Cover Page Interactive Data File (Exhibit 104). No financial statements, earnings data, material transactions, guidance, or additional substantive financial information are included. The report was signed by CFO Kyle Moran on August 5, 2025.

Insights

Financial Analyst

TL;DR Routine investor update; no new financial metrics or material events were disclosed.

The 8-K reports a furnished corporate presentation dated August 5, 2025, posted on the company IR site and furnished as Exhibit 99.1. As a Financial Analyst, I view this as not impactful to valuations: it contains no revenue, earnings, guidance, or material transaction detail. Investors should review the posted slides for any strategic or pipeline framing, but the filing itself provides only administrative disclosure under Item 7.01 and Exhibit 99.1. No immediate change to financial estimates is warranted based solely on this filing.

Corporate Governance Expert

TL;DR Compliance-focused disclosure; furnishes presentation under Reg FD and clarifies non-filing status of exhibit.

The company follows standard Regulation FD practice by furnishing its investor presentation and stating it is "furnished and not filed," limiting Section 18 liability and preventing automatic incorporation by reference. Exhibit disclosures include 99.1 (presentation) and 104 (interactive cover page). From a governance perspective this is not impactful—it demonstrates routine investor communications and proper SEC reporting form and language but conveys no material governance changes or new obligations.

false 0001631574 0001631574 2025-08-05 2025-08-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2025

WAVE LIFE SCIENCES LTD.

(Exact name of registrant as specified in its charter)

Singapore		001-37627		98-1356880
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7 Straits View #12-00, Marina One
East Tower
Singapore		018936
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: +65 6236 3388

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
$0 Par Value Ordinary Shares		WVE		The Nasdaq Global Market

Item 7.01 Regulation FD Disclosure.

From time to time, Wave Life Sciences Ltd. (the “Company”) presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On August 5, 2025, the Company updated its corporate presentation, which is available on the “For Investors & Media” section of the Company’s website at http://ir.wavelifesciences.com/. This presentation is also furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit relating to Item 7.01 is furnished and not filed:

Exhibit No.		Description
99.1		Corporate Presentation of Wave Life Sciences Ltd. dated August 5, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WAVE LIFE SCIENCES LTD.
By:		/s/ Kyle Moran
		Kyle Moran
		Chief Financial Officer

Date: August 5, 2025

FAQ

What did Wave Life Sciences (WVE) disclose in the August 5, 2025 8-K?

The 8-K discloses an updated corporate presentation dated August 5, 2025, furnished as Exhibit 99.1 and posted on the company's investor website.

Is the presentation in the 8-K considered filed with the SEC?

No. The company explicitly states the presentation is furnished and not filed for purposes of Section 18 of the Exchange Act.

Where can investors access the furnished corporate presentation?

The presentation is available in the "For Investors & Media" section at http://ir.wavelifesciences.com/.

Does the 8-K include financial statements or material transactions?

No. The report contains no financial statements, earnings, guidance, or material transaction disclosures.

Who signed the Form 8-K and when?

The report was signed by Kyle Moran, Chief Financial Officer, on August 5, 2025.